Table 5, COI Declaration for Canadian Stroke Consortium — Clinician 3 - Andexanet Alfa (Ondexxya)

Company	$0 to 5,000	$5,001 to 10,000	$10,001 to 50,000	In Excess of $50,000
Astra Zeneca Canada	X	—	—	—

Andexanet Alfa (Ondexxya): CADTH Reimbursement Review: Therapeutic area: Reversal of FXa inhibitor anticoagulant effects [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.

Copyright © 2024 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 5COI Declaration for Canadian Stroke Consortium — Clinician 3